Figure S6 from Antitumor Immune Responses in B2M-Deficient Cancers
Year: 2023
Type: other
Abstract: Bempegaldesleukin to reverse resistance in JAK1-deficient tumors. (A) In vivo tumor growth curves for MC38 JAK1-KO tumors treated with 0.8 mg/kg intravenous bempegaldesleukin every 9 days x 2 doses, or anti-PD-1 therapy, or the combination. Data represented as mean ± SEM from an n of 4 per group. The arrow indicates the days of treatment with bempegaldesleukin or when anti -PD-1 therapy was started. Dunnett multiple comparisons tests for control versus anti-PD-1, or bempegaldesleukin, or bempegaldesleukin plus anti-PD-1. ns, not significant; ****, P < 0.0001. (B) The measure of MHC class I expression by flow cytometry after IFNγ stimulation in MC38 WT, JAK1-KO and B2M-KO. JAK1-KO maintains its MHC class I basal expression upon IFNγ. Histograms represent changes in MFI by flow cytometry.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4389239585